Patient assistance programs

For over 10 years, the Renassist® team has been helping patients with and without prescription drug coverage identify the Renvela® (sevelamer carbonate) reimbursement solution that is right for them. Call a Renassist case manager for assistance or explore the options below.

  • No prescription insurance

    Renassist Patient Assistance Program (RPAP)
    RPAP is designed for patients with financial need who do not have coverage for Renvela® (sevelamer carbonate) (and/or Hectorol® [doxercalciferol injection]) under any prescription drug benefit, including commercial insurance, Medicare, Medicaid, or other government insurance programs. Learn more.

  • Standard Medicare Part D

    Part D Assistance Program (PDAP)
    PDAP provides a free supply of Renvela® to eligible Medicare Part D patients who cannot afford their copayments or co-insurance for Renvela®. Learn more.

  • Commercial prescription insurance

    RenValueSM
    A Sanofi-sponsored program, the RenValue coupon program helps cover the costs of Renvela® for qualified patients with or without prescription insurance. Learn more.

Could your patient be paying less than $7 for Renvela® (sevelamer carbonate)?

Read patient stories

Quick tips

Download a list of reimbursement tips to share with your patients.

Indication for Renvela and Renagel
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients
with chronic kidney disease (CKD) on dialysis.

Important Safety Information for Renvela and Renagel
  • Sevelamer is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Indications
  • Hectorol Injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
  • Hectorol capsules are indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease not on dialysis and patients with chronic kidney disease on dialysis.

Important Safety Information for Hectorol
  • You should not take Hectorol if you have a history of abnormally high calcium blood levels (hypercalcemia) or if you have very high vitamin D levels.
  • Overdosage of any form of vitamin D is dangerous and may require emergency attention.
  • Before taking Hectorol, tell your doctor if you have ever had an irregular heartbeat or seizure, or if you are taking any digitalis drugs (or cholestyramine if you are taking Hectorol capsules).
  • Serum bicarbonate and chloride levels should be monitored.
  • Do not take other vitamin D related drugs if you are currently taking Hectorol.
  • It is important for anyone taking Hectorol to talk to their doctor before taking any non-prescription drugs or magnesium-containing antacids, supplements and herbal preparations and to adhere to instructions about following a low phosphorus diet and calcium supplementation.
  • Your doctor should monitor your calcium, phosphorus and PTH levels.
  • Tell your doctor if you experience symptoms of hypercalcemia such as weakness, headache, drowsiness, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, metallic taste and loss of appetite.
  • Your doctor should check and treat you for nutritional vitamin D deficiency before starting you on Hectorol capsules.
  • The main side effects of treatment with Hectorol injection are hypercalcemia, hyperphosphatemia, and oversuppression of PTH. The main side effects of treatment with
  • Hectorol capsules are hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of PTH. Your doctor may ask you questions to see if you are experiencing any symptoms related to these conditions.
  • During treatment, your doctor may change your dose of Hectorol as well as the dose of your phosphate binder.
  • Common side effects seen in Hectorol-treated patients on dialysis were swelling, headache, ill feeling, nausea/vomiting, dizziness, shortness of breath, itching and slow heartbeat.
  • Common side effects seen in patients taking Hectorol capsules with Stage 3 or Stage 4 chronic kidney disease were infection, chest pain, constipation, indigestion, anemia, dehydration, depression, muscle stiffness, insomnia, tingling, increased cough, shortness of breath and runny/stuffy nose.
  • Tell your doctor if you are pregnant or nursing.
  • This drug should be used with caution if you have impaired liver function.

    Terms and conditions  |  Privacy policy  |  Prescribing Information for Renvela®  |  Prescribing Information for Renagel®  |  Contact Renassist  |  Resources